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Healthcare Needs Nanotechnology 
 Industry Issues 
 Rapidly eroding patent 
protection 
 Increasing need for 
more effective products 
 Growing regulatory 
pressures 
 Accelerating cost 
pressure and proof-of-
cost benefit 
 
 
“We spend billions each year to 
get innovation, but where does 
innovation come from, and how 
do we get more of it?... We 
need transformational change.” 
 
- Bernard Munos, InnoThink Center 
for Research in Biomedical Innovation 
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Nanotechnology: The Potential to Transform Product 
Development 
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Nanomedicine market Estimated to reach $130.9 billion  
Source: BCC Nanomedice Market Forecast - 2012 
Chantecaille ™ 
Abraxane™ Sunstick™ 
“Nano-Stars”- Northwestern University  SiO2 Particles - MIT 
“Nano-CLuster”- Univ. of Kansas  
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FDA Advisory Committee Comments 
■ “Nanotechnology has great potential to impact 
medical research and drug discovery” 
■ Further work on characterization should be done 
 Evaluating how nanoparticle size and shape effect drug PK 
and PD 
• Change in particle size can affect performance 
 Traditional analytics may not be adequate 
■ Further guidance needed 
 Including additional studies required for a change to 
nanosized API 
From Aug meeting of FDA Advisory Committee on 
Pharmaceutical Sciences and Clinical Pharmacology  
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Key Ingredients for Continued Strong Growth of 
Nanotechnology in Health Care? 
■Compelling product efficacy and safety data 
■Multi-disciplinary collaborations 
■ Scalable, well-characterized, cost-effective 
manufacturing 
■Clear and reasonable regulatory guidelines 
■ Funding 
■ Evangelical pursuit and excellent execution 
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Liquidia Corporate Profile 
 Founded in 2004 
 Located in RTP, NC 
 Novel technology platform 
 Strong patent protections 
 Experienced management 
team 
 Robust investor syndicate 
 Transformative partnerships 
 
 
 
Story titled; “Particle Technology Delivers Medicines and Vaccines” 
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 Gaining Momentum 
Liquidia is poised to be a leader in the development of nanotechnology-based 
healthcare products and a catalyst for the growth anticipated across this industry. 
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Precise.  Powerful.  PRINT® 
■PRINT (Particle Replication in 
Non-wetting Templates) Platform: 
 Utilizes the precision of the 
microelectronics industry 
 Transforms particle engineering and 
product development 
 Offers a scalable, cost-effective 
manufacturing platform 
 
PRINT is revolutionizing the way that 
companies engineer healthcare products 
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Library of Precisely Engineered Particles 
PRINT is the only technology in the world that enables independent design of particle 
size, shape and chemistry 
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PRINT Manufacturing Advantages 
 Quality by Design: 
 Precise control of size, shape and composition 
 Uniform particle population, easily characterized  
 Demonstrated batch-to-batch consistency 
 Scalable cGMP Manufacturing Platform: 
 Existing cGMP manufacturing capability 
 Leveraging the breadth of Roll-to-Roll technology 
 Commercially Relevant Scale and Cost 
 Minimal Facilities Burden: 
 Small footprint, low CapEx equipment 
 Low bioburden process, minimal water needs 
(reduced maintenance and monitoring cost) 
 No exotic utilities (drop-in-place equipment) 
 Concept for aseptic manufacturing, if required 
 
 
 
 
 
 
 
 
Supported by robust IP portfolio and “know-how”: protection from competition 
265 ± 10 
nm 
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PRINT Particles have Broad Product Benefits 
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PRINT Benefits Can Drive Products in Many Large 
Markets 
PRINT offers the potential to create innovative products across large markets 
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Liquidia Enables Next Generation Vaccines 
O
O
O
O
O
O
O
O
1st Generation:  
Whole Pathogens 
2nd Generation: 
Sub-Unit and Nucleic Acids 
Sub-Unit Protein 
Sub-Unit  
Polysaccharide Conjugates 
Nucleic Acids: 
Vectored or Naked 
Protein-Adjuvant Co-delivery 
Virtual-conjugates 
Synthetic Delivery System 
Next  Generation: 
PRINT  Vaccines 
O
O
O
O
O
O
O
O
PRINT Vaccines Offer the Potential for Rationally Designed Vaccines 
Optimizing Efficacy, Safety and Cost for New and Existing Targets 
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 Controlled loading of 
components (antigens, proteins, 
adjuvants, etc.) to optimize 
safety, efficacy and cost 
 Unique particle sizes and shapes 
to enhance immune response 
and improve manufacturing 
 Highly consistent, scalable 
manufacturing with attractive 
vaccine COGS 
Anti-H3 HA IgG response after a single injection 
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1x1x10 micron PRINT Particles 
Potential Benefits of PRINT Vaccines 
Avian Influenza 
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Particle #1
AD: 0.65
GSD: 1.25
Particle #3
AD: 2.45
GSD: 1.49
Particle #2
AD: 1.09
GSD: 1.25
Tunable Aerodynamic Properties 
Marketed DPI 
Product 
    PRINT DPI 
Fill wt. 5 mg 5 mg 
MMAD 3.4 m 2.2 m 
Respir. Dose 1200 g 2900 g 
FPF 25% 83% 
< 1.6 m 220 g 1000 g 
Enhanced Pulmonary Delivery 
PRINT has Potential in Pulmonary Medicine 
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Unlocking the Next Frontier in Cancer Therapeutics 
Novel Therapeutics and 
Targeting Molecules 
   Small molecules 
   Biologics (e.g. 
engineered proteins) 
 
Intracellular vesicle 
PRINT particles 
PRINT nanoparticles for 
systemic and intracellular 
delivery 
 
Surface targeting for 
enhanced selectivity 
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Opportunities for PRINT in Ocular Drug Delivery 
 Iontophoretic delivery 
Independently modulate carrier charge and 
drug loading 
 
 Local delivery with “engineered” 
particle designs that: 
 Minimize clearance 
 Optimize cell uptake 
 Control release kinetics 
 
 Extended release of small 
molecules, biologics, siRNA 
Active: +4 mA x 5 min 
n = 2  
LP 
C 
PRINT particles can translocate sclera, 
conjunctiva (w/ Eyegate)  
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Business Model: Prioritize Products and Markets for 
Partnerships or Internal Development 
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High Value, 
 High Risk 
Near-Term Recurring 
Commercial Revenue 
PAH 
Cancer 
Partnerships drive 
revenue, validation and 
capabilities 
Pulmonary 
Vaccines 
Select Programs offer 
capitally efficient path to 
products or value 
inflection milestones 
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Liquidia’s Plan for Successful Nano Health Care 
Product Commercialization 
■ Portfolio of products 
 select portfolio of products that balance risk and return 
■ Compelling Product Benefits 
 demonstrate benefit and safety of PRINT products and 
mechanistic understanding 
■ Manufacturing 
 leverage robust, regulatory friendly manufacturing platform 
■ Partnerships Matter 
 find motivated, experience and collaborative partners 
■ Execution 
 Rapidly deliver on smart, capital efficient plan 
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One Company. One Incredibly Powerful Platform. 
Through its novel technology platform and unrivaled IP 
positions, Liquidia is poised to be a leader in the 
development and manufacturing of nanotechnology-
based healthcare products and a catalyst for the growth 
anticipated across this industry. 
LIQUIDIA TECHNOLOGIES 
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